. Author manuscript; available in PMC: 2022 Oct 28.

Published in final edited form as: Clin Liver Dis. 2019 Aug;23(3):417–432. doi: 10.1016/j.cld.2019.04.008

Table 2:

Comparison of Recommendations for Prevention of Hepatitis B

	WHO	AASLD
Primary prevention	Universal HBV vaccination to all infants	Universal HBV vaccination to all infants
Catch up vaccination	HBV vaccination of non-immune high-risk groups	HBV vaccination of non-immune high-risk groups
Prevention of mother to child transmission	HBIG + HBV vaccination to all infants born to HBsAg/HBeAg positive mothers HBV vaccination to all infants born to HBsAg positive/HBeAg negative mothers Antiviral therapy not recommended for highly viremic mothers	HBIG + HBV vaccination within 12 hours of birth to all infants born to HBsAg positive mothers Antiviral therapy (tenofovir) initiated at 28 to 32 weeks of gestation for pregnant women with serum HBV DNA levels >200,000 IU/ml until 4 weeks postpartum